Form 4: Blueprint Medicines Acquired by Sanofi Subsidiary; Director Goldberg Disposes Shares and Options

Blueprint Medicines Corporation has been acquired by a Sanofi subsidiary through a tender offer and merger, resulting in Director Mark Alan Goldberg disposing of his common stock and stock options for cash and contingent value rights.

Summary

• Blueprint Medicines Corporation (BPMC) was acquired by Rothko Merger Sub, Inc., an indirect wholly-owned subsidiary of SANOFI, through a tender offer and merger.
• The acquisition was completed for $129.00 per share in cash, plus one contractual contingent value right (CVR) per share.
• The merger became effective on July 17, 2025, with Blueprint Medicines surviving as an indirect wholly-owned subsidiary of SANOFI.
• Director Mark Alan Goldberg disposed of 3,902 shares and an additional 18,254 shares of common stock, resulting in zero direct beneficial ownership of common stock.
• All outstanding restricted stock units (RSUs), whether vested or unvested, were cancelled and converted into the right to receive the offer consideration.
• All outstanding stock options, whether vested or unvested, became fully vested, cancelled, and converted into the right to receive the cash offer price (less the applicable exercise price) and one CVR per share.
• An exception applies to 50% of options issued in calendar year 2025, which converted into cash-based awards subject to continued vesting, based on the cash offer price (less the applicable exercise price) plus one CVR.
• Mark Alan Goldberg disposed of a total of 47,954 stock options across various exercise prices, resulting in zero direct beneficial ownership of derivative securities.

Sentiment

Score: 8

Explanation: The document reports the successful completion of a merger and tender offer, providing liquidity and a premium to shareholders. While the CVR introduces some uncertainty, the immediate cash component is positive. For the reporting person, it signifies the successful monetization of their equity holdings.

Positives

• Shareholders received a cash offer price of $129.00 per share, plus a contingent value right (CVR), indicating a premium for their shares.
• All outstanding restricted stock units (RSUs) and stock options, whether vested or unvested, were converted into the right to receive the offer consideration or cash-based awards, providing liquidity and value to equity holders.
• The acquisition by SANOFI, a major pharmaceutical company, provides a clear exit strategy and potential for the acquired assets to be further developed under a larger entity.

Negatives

• Blueprint Medicines Corporation ceased to be an independent publicly traded entity, becoming an indirect wholly-owned subsidiary of SANOFI.
• Existing shareholders no longer hold equity in Blueprint Medicines Corporation directly.

Risks

• The value of the contingent value rights (CVRs) is dependent on the achievement of certain future milestones, introducing uncertainty regarding the full value of the offer consideration.

Future Outlook

NA

Industry Context

The acquisition of Blueprint Medicines by Sanofi reflects a broader trend in the pharmaceutical and biotechnology sectors where larger established companies acquire innovative smaller firms to expand their pipeline and intellectual property, particularly in specialized therapeutic areas. This transaction allows Sanofi to integrate Blueprint Medicines' assets and expertise, potentially strengthening its market position.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $129.00 per share in cash plus one CVR, providing a clear exit and liquidity for their investment.
• Employees: While not explicitly stated, the merger could lead to integration efforts, potential restructuring, or changes in employment terms, especially for those with stock options subject to continued vesting.
• Management/Directors: Directors like Mark Alan Goldberg monetized their equity holdings and are no longer subject to Section 16 obligations, indicating a change in their relationship with the now-private entity.

Next Steps

• The contingent value rights (CVRs) will be paid upon the achievement of certain milestones, which are not detailed in this filing.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, SEC Form 4, Stock Options, Restricted Stock Units, Contingent Value Rights, Corporate Governance, Director Share Disposal, Pharmaceuticals, Biotechnology